Development of a metabolic biosignature for detection of early Lyme disease.
Development of a metabolic biosignature for detection of early Lyme disease.
复制标题
开发用于检测早期莱姆病的代谢生物特征。
DOI：
10.1093/cid/civ185
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Belisle,JohnT
中科院分区：
文献类型：
--
作者：
Molins,ClaudiaR;Ashton,LauraV;Wormser,GaryP;Hess,AnnM;Delorey,MarkJ;Mahapatra,Sebabrata;Schriefer,MartinE;Belisle,JohnT
Background.Early Lyme disease patients often present to the clinic prior to developing a detectable antibody response toBorrelia burgdorferi, the etiologic agent. Thus, existing 2-tier serology-based assays yield low sensitivities (29%–40%) for early infection. The lack of an accurate laboratory test for early Lyme disease contributes to misconceptions about diagnosis and treatment, and underscores the need for new diagnostic approaches.Methods.Retrospective serum samples from patients with early Lyme disease, other diseases, and healthy controls were analyzed for small molecule metabolites by liquid chromatography-mass spectrometry (LC-MS). A metabolomics data workflow was applied to select a biosignature for classifying early Lyme disease and non-Lyme disease patients. A statistical model of the biosignature was trained using the patients' LC-MS data, and subsequently applied as an experimental diagnostic tool with LC-MS data from additional patient sera. The accuracy of this method was compared with standard 2-tier serology.Results.Metabolic biosignature development selected 95 molecular features that distinguished early Lyme disease patients from healthy controls. Statistical modeling reduced the biosignature to 44 molecular features, and correctly classified early Lyme disease patients and healthy controls with a sensitivity of 88% (84%–95%), and a specificity of 95% (90%–100%). Importantly, the metabolic biosignature correctly classified 77%–95% of the of serology negative Lyme disease patients.Conclusions.The data provide proof-of-concept that metabolic profiling for early Lyme disease can achieve significantly greater (P< .0001) diagnostic sensitivity than current 2-tier serology, while retaining high specificity.
登录
查看更多内容
DOI：
10.1093/cid/ciu397
发表时间：
2014-09-01
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Hinckley AF;Connally NP;Meek JI;Johnson BJ;Kemperman MM;Feldman KA;White JL;Mead PS
通讯作者：
Mead PS
影响因子：
29.4
作者：
Lara-Avila, Samuel;Moth-Poulsen, Kasper;Kubatkin, Sergey
通讯作者：
Kubatkin, Sergey
莱姆病血清学检测中非特异性密螺旋体抗体的交叉反应
影响因子：
9.4
作者：
L. Magnarelli;James N. Miller;John F. Anderson;G R Riviere
通讯作者：
G R Riviere
影响因子：
158.5
作者：
G. Wormser
通讯作者：
G. Wormser
影响因子：
5.8
作者：
Friedman, Jerome;Hastie, Trevor;Tibshirani, Rob
通讯作者：
Tibshirani, Rob